OR WAIT null SECS
The new group is made up of over 15 scientists who formerly worked in GSK's computational biology and genetics departments
PAREXEL International Corporation now offers a genomic medicine team to help with strategic and operational services designed to accelerate drug development and to support regulatory and payer approval processes. This expertise is becoming increasingly important, PAREXEL executives say, as biopharmaceutical companies apply genomics to more drug discovery and development projects in order to better understand the genetic basis of disease, drug targets, and drug response.
Over the next five years, the number of personalized medicines in the pipeline is expected to increase significantly. In 2015, one fifth of all the new drugs approved by FDA were targeted therapies, while drug mechanisms with genetic evidence have been found to be more likely to receive approval than those without them.
“Recently, ‘precision medicine’ and ‘personalized medicine’ have become household terms, and genomic research is the key to developing targeted therapies. By applying innovative and state-of-the-art methodologies, we work with our clients to understand how genes impact an individual’s response to treatment – and why people who receive the same treatment may respond differently,” said Sy Pretorius, M.D., Chief Scientific Officer, PAREXEL. “PAREXEL’s Genomic Medicine team leverages genomic information across more than 10 therapeutic areas to help biopharmaceutical companies discover, develop, and secure regulatory and payer approval for their new medicines.”
The group is made up of more than 15 scientists. For more information, please visit www.parexel.com/genomics.